Barclays PLC Concert Pharmaceuticals, Inc. Transaction History

Barclays PLC

  • $377 Billion
  • Q3 2024

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023
BUY
$4.34 - $5.84 $517,484 - $696,338
119,236 Added 26.34%
571,990 $3.34 Million
Q3 2022

Nov 03, 2022
BUY
$4.27 - $7.2 $321,706 - $542,455
75,341 Added 19.96%
452,754 $3.03 Million
Q2 2022

Aug 12, 2022
BUY
$2.8 - $6.36 $934,525 - $2.12 Million
333,759 Added 764.56%
377,413 $1.59 Million
Q4 2021

Feb 14, 2022
SELL
$2.69 - $4.22 $10,291 - $16,145
-3,826 Reduced 8.06%
43,654 $138,000
Q3 2021

Nov 09, 2021
BUY
$3.17 - $4.15 $1,410 - $1,846
445 Added 0.95%
47,480 $156,000
Q2 2021

Aug 13, 2021
SELL
$3.77 - $5.24 $80,546 - $111,952
-21,365 Reduced 31.24%
47,035 $198,000
Q1 2021

May 13, 2021
BUY
$4.86 - $13.07 $71,160 - $191,370
14,642 Added 27.24%
68,400 $341,000
Q4 2020

Feb 11, 2021
BUY
$9.48 - $12.84 $321,609 - $435,597
33,925 Added 171.05%
53,758 $680,000
Q3 2020

Nov 12, 2020
BUY
$8.67 - $10.82 $35,442 - $44,232
4,088 Added 25.96%
19,833 $195,000
Q2 2020

Aug 12, 2020
BUY
$7.8 - $11.52 $54,935 - $81,135
7,043 Added 80.94%
15,745 $156,000
Q1 2020

May 13, 2020
SELL
$5.98 - $13.09 $80,161 - $175,471
-13,405 Reduced 60.64%
8,702 $76,000
Q4 2019

Feb 10, 2020
BUY
$5.71 - $9.22 $60,828 - $98,220
10,653 Added 93.01%
22,107 $204,000
Q3 2019

Nov 14, 2019
SELL
$5.88 - $12.35 $31,934 - $67,072
-5,431 Reduced 32.16%
11,454 $67,000
Q2 2019

Aug 14, 2019
SELL
$9.44 - $13.12 $652,766 - $907,234
-69,149 Reduced 80.37%
16,885 $203,000
Q1 2019

May 15, 2019
BUY
$12.07 - $17.54 $1.02 Million - $1.48 Million
84,114 Added 4380.94%
86,034 $1.04 Million
Q4 2018

Feb 14, 2019
SELL
$11.25 - $16.17 $202,837 - $291,545
-18,030 Reduced 90.38%
1,920 $25,000
Q3 2018

Nov 14, 2018
BUY
$12.82 - $17.88 $158,121 - $220,531
12,334 Added 161.95%
19,950 $297,000
Q2 2018

Aug 14, 2018
SELL
$16.83 - $21.66 $10,889 - $14,014
-647 Reduced 7.83%
7,616 $129,000
Q1 2018

May 15, 2018
SELL
$19.24 - $28.03 $238,941 - $348,104
-12,419 Reduced 60.05%
8,263 $189,000
Q4 2017

Feb 14, 2018
BUY
$13.96 - $29.05 $177,292 - $368,935
12,700 Added 159.11%
20,682 $534,000
Q3 2017

Nov 14, 2017
BUY
$13.91 - $15.31 $111,029 - $122,204
7,982
7,982 $118,000

Others Institutions Holding CNCE

# of Institutions
1
Shares Held
0
Call Options Held
0
Put Options Held
0
View Full List

About CONCERT PHARMACEUTICALS, INC.

CNCE Quotes by TradingView
  • Ticker CNCE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,934,600
  • Description
  • Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has s...
More about CNCE
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email